Remedium Lifecare Limited Charts Long-Term Growth with Global Subsidiary, Export Contract and Strong Investor Support
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Remedium Lifecare Limited (formerly Roxy Exports Limited) has shared a press release outlining its long-term growth strategy in the pharma trade and CDMO space. The company set up a wholly owned subsidiary, Remlife Global Pte. Ltd., in Singapore to serve as its global commercial and capital markets interface. In February 2025, it secured a multi-year export contract worth ₹182.7 crore (about USD 21 million) with a leading international pharmaceutical distributor. A recently concluded rights issue saw strong investor participation, and proceeds are being deployed toward R&D upgrades, CDMO infrastructure, and expansion into regulated and semi-regulated markets. The company has also partnered with Jia Yu Lifesciences Pte. Ltd. through its Singapore arm to explore sustainable, animal-free raw material bioprocesses.
This is a positive update for shareholders — it signals international expansion, a sizable export order, and capital raising success, all of which can support future revenue growth and valuation. However, no immediate manufacturing capacity expansion was announced, so near-term financial impact may be limited.